# Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

Source: https://onco.cc/trials/nct05201404/  
OnCo record `nct05201404` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Namodenoson in hepatocellular carcinoma, run by Can-Fite BioPharma, now recruiting.

## Summary

Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis is a phase 3 interventional study registered as NCT05201404 by Can-Fite BioPharma, with 471 participants planned, started 2023-03-15 and due to reach its primary completion in 2026-02. Interventions recorded: Namodenoson and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05201404
- Phase: 3
- Setting: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
- Sponsor: Can-Fite BioPharma
- Enrolled: 471

## Sources

- ClinicalTrials.gov NCT05201404: https://clinicaltrials.gov/study/NCT05201404

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- companies: [Can-Fite BioPharma](https://onco.cc/companies/can-fite/)

---
JSON: https://onco.cc/api/v1/entities/nct05201404.json